Plant made anti-HIV microbicides-A field of opportunity

Biotechnology Advances

Volumn 30, Issue 6, 2012, Pages 1614-1626

  Lotter Stark, Hester C T ^a   Rybicki, Edward P ^b   Chikwamba, Rachel K ^a  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antibodies; HIV; Lectins; Microbicides; Plant expression

Indexed keywords

ALTERNATIVE PRODUCTION SYSTEMS; ANTI-HIV; CURRENT PRODUCTION; HIV; IN-VITRO; LECTINS; LOW COSTS; MICROBICIDES; PLANT EXPRESSION; PROTEIN EXPRESSIONS; PROTEIN PURIFICATION; VECTOR SYSTEMS;

ANTIBODIES; PEPTIDES; PRODUCTION ENGINEERING; VIRUSES;

DISEASES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEUTRALIZING ANTIBODY; PEPTIDE;

ANTIBODY; BIOTECHNOLOGY; DISEASE TREATMENT; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; NEUTRALIZATION; PEPTIDE; PROTEIN; PURIFICATION;

BIOSYNTHESIS; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PLANT; REVIEW; VIROLOGY;

ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; HIV; HIV INFECTIONS; HUMANS; PEPTIDES; PLANTS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84867715142     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2012.06.002     Document Type: Review

References (176)

1. Armbruster C., Stiegler G.M., Vcelar B.A., Jäger W., Michael N.L., Vetter N., et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002, 16:227-233.
2. Armbruster C., Stiegler G.M., Vcelar B.A., Jäger W., Köller U., Jilch R., et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004, 54:915-920.
3. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., et al. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One 2009, 4:e4792.
4. Baba M. Recent advances of CCR5 antagonists. Curr Opin HIV AIDS 2006, 1:367-372.
5. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal Simian-Human immunodeficiency virus infection. Nat Med 2000, 6:200-206.
6. Balzarini J. Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120. Curr Opin HIV AIDS 2006, 1:355-360.
7. Balzarini J., Van Herrewege Y., Vermeire K., Vanham G., Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 2007, 71:3-11.
8. Banta L.M., Montenegro M. Agrobacterium and plant biotechnology. Agrobacterium: from biology to biotechnology 2008, 73-147. Department of Biology, Williams College, Williamstown, MA 01267, USA. T. Tzfira, V. Citovsky (Eds.).
9. Barre A., Van Damme E.J., Peumans W.J., Rouge P. Structure-function relationship of monocot mannose-binding lectins. Plant Physiol 1996, 112:1531-1540.
10. Barrientos L.G., Gronenborn A.M. The domain-swapped dimer of cyanovirin-N contains two sets of oligosaccharide binding sites in solution. Biochem Biophys Res Commun 2002, 298:598-602.
11. Barrientos L.G., O'Keefe B.R., Bray M., Sanchez A., Gronenborn A.M., Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein, GP1, 2 and inhibits infectivity of Ebola virus 1. Antiviral Res 2003, 58:47-56.
12. Barrientos L.G., Lasala F., Delgado R., Sanchez A., Gronenborn A.M. Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity. Structure 2004, 12:1799-1807.
13. Bendandi M., Marillonnet S., Kandzia R., Thieme F., Nickstadt A., Herz S., et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 2010, 21:2420-2427.
14. Bewley C.A., Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man8 D1D3 and Man9 with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J Am Chem Soc 2001, 123:3892-3902.
15. Biemelt S., Sonnewald U., Galmbacher P., Willmitzer L., Müller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003, 77:9211-9220.
16. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78:13232-13252.
17. Bortesi L., Rossato M., Schuster F., Raven N., Stadlmann J., Avesani L., et al. Viral and murine interleukin-10 are correctly processed and retain their biological activity when produced in tobacco. BMC Biotechnol 2009, 9:22.
18. Botos I., Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol 2005, 88:233-282.
19. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997, 41:1521-1530.
20. Buckheit R.W., Watson K.M., Morrow K.M., Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antivir Res 2010, 85:142-158.
21. Bulgheresi S., Schabussova I., Chen T., Mullin N.P., Maizels R.M., Ott J.A. A new C-type lectin similar to the human immunoreceptor DC-SIGN mediates symbiont acquisition by a marine nematode. Appl Environ Microbiol 2006, 72:2950-2956.
22. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
23. Campiani G., Ramunno A., Maga G., Nacci V., Fattorusso C., Catalanotti B., et al. Non-Nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002, 8:615-657.
24. Castilho A., Strasser R., Stadlmann J., Grass J., Jez J., Gattinger P., et al. In planta protein sialylation through over-expression of the respective mammalian pathway. J Biol Chem 2010, 285:15923-15930.
25. Castilho A., Bohorova N., Grass J., Bohorov O., Zeitlin L., Whaley K., et al. Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS One 2011, 6(10):e26040.
26. Chen Q., He J., Phoolcharoen W., Mason H.S. Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Vaccines 2011, 7:331-338.
27. Chiba H., Inokoshi J., Nakashima H., Omura S., Tanaka H. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. Biochem Biophys Res Commun 2004, 316:203-210.
28. Cihlar T. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. Curr Opin HIV AIDS 2006, 1:373-379.
29. Coëffier E., Clément J., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2001, 19:684-693.
30. Cunha N.B., Murad A.M., Ramos G.L., Maranhão A.Q., Brígido M.M., Araújo A.C.G., et al. Accumulation of functional recombinant human coagulation factor IX in transgenic soybean seeds. Transgenic Res 2011, 20:841-855.
31. Cunha N.B., Murad A.M., Cipriano T.M., Araújo A.C.G., Aragão F.J.L., Leite A., et al. Expression of functional recombinant human growth hormone in transgenic soybean seeds. Transgenic Res 2011, 20:811-826.
32. Cutler B., Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008, 8:685-697.
33. Davis K.R. Development of novel vaccines and therapeutics using plant-based expression systems. Annual Report prepared for: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 2010.
34. De Muynck B., Navarre C., Boutry M. Production of antibodies in plants: status after twenty years. Plant Biotechnol J 2010, 8:529-563.
35. De Rosny E., Vassell R., Jiang S., Kunert R., Weiss C.D. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004, 78:2627-2631.
36. Dey B., Lerner D.L., Lusso P., Boyd M.R., Elder J.H., Berger E.A. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000, 74:4562-4569.
37. Doncel G.F., Clark M.R. Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers. Antiviral Res 2010, 88:S10-S18.
38. Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci 2010, 107:13800-13805.
39. Eggink D., Melchers M., Sanders R.W. Antibodies to HIV-1: aiming at the right target. Trends Microbiol 2007, 15:291-294.
40. Emau P., Tian B., O'Keefe B., Mori T., McMahon J., Palmer K., et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 2007, 36:244-253.
41. Faye L., Gomord V. Success stories in molecular farming-a brief overview. Plant Biotechnol J 2010, 8:525-528.
42. Férir G., Palmer K.E., Schols D. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 2011, 417:253-258.
43. Fischer R., Schillberg S., Hellwig S., Twyman R.M., Drossard J. GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv 2012, 30:434-439.
44. Floss D.M., Sack M., Stadlmann J., Rademacher T., Scheller J., Stöger E., et al. Biochemical and functional characterization of anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant Biotechnol J 2008, 6:379-391.
45. Francois K.O., Balzarini J. Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Med Res Rev 2010, 23:1-39. [Jun].
46. Franquelim H.G., Chiantia S., Veiga A.S., Santos N.C., Schwille P., Castanho M.A. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes. AIDS 2011, 25:419-428.
47. Fromme R., Katiliene Z., Giomarelli B., Bogani F., McMahon J., Mori T., et al. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity. Biochemistry 2007, 46:9199-9207.
48. Garg A.B., Nuttall J., Romano J. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 2009, 19:143-150.
49. Garg S., Goldman D., Krumme M., Rohan L.C., Smoot S., Friend D.R. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 2010, S19-S29.
50. Geyer H., Holschbach C., Hunsmann G., Schneider J. Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 1988, 263:11760-11767.
51. Giddings G., Allison G., Brooks D., Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 2000, 18:1151-1155.
52. Giomarelli B., Provvedi R., Meacci F., Maggi T., Medaglini D., Pozzi G., et al. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 2002, 16:1351-1356.
53. Giomarelli B., Schumacher K.M., Taylor T.E., Sowder R.C., Hartley J.L., McMahon J.B., et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture. Protein Expr Purif 2006, 47:194-202.
54. Giritch A., Marillonnet S., Engler C., Van Eldik G., Botterman J., Klimyuk V., et al. Rapid high-yield expression of full-size IgG antibodies in plants co-infected with noncompeting viral vectors. Proc Natl Acad Sci U S A 2006, 103:14701-14706.
55. Gleba Y., Klimyuk V., Marillonnet S. Magnifection-a new platform for expressing recombinant vaccines in plants. Vaccine 2005, 23:2042-2048.
56. Goldstein I.J., Hayes C.E. The lectins: carbohydrate-binding proteins of plants and animals. Adv Carbohydr Chem Biochem 1978, 35:127-340.
57. Gomord V., Chamberlain P., Jefferis R., Faye L. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol 2005, 23:559-565.
58. Gomord V., Fitchette A., Menu-Bouaouiche L., Saint-Jore-Dupas C., Plasson C., Michaud D., et al. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 2010, 8:564-587.
59. Gustafson K.R., Sowder R.C., Henderson L.E., Cardellina J.H., McMahon J.B., Rajamani U., et al. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (Human Immunodeficiency Virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun 1997, 238:223-228.
60. Helle F., Wychowski C., Vu-Dac N., Gustafson K.R., Voisset C., Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006, 281:25177-25183.
61. Hessell A.J., Hangartner L., Hunter M., Havenith C.E.G., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
62. Ba-L. J Virol 2010, 84:1302-1313.
63. Hoorelbeke B., Huskens D., Ferir G., Francois K.O., Takahashi A., Van Laethem K., et al. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 2010, 54:3287-3301.
64. Hu Q., Frank I., Williams V., Santos J.J., Watts P., Griffin G.E., et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004, 199:1065-1075.
65. Huang Z., Phoolcharoen W., Lai H., Piensook K., Cardineau G., Zeitlin L., et al. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 2010, 106:9-17.
66. Huskens D., Vermeire K., Vandemeulebroucke E., Balzarini J., Schols D. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 2008, 40:2802-2814.
67. Inokoshi J., Chiba H., Asanuma S., Takahashi A., Omura S., Tanaka H. Molecular cloning of actinohivin, a novel anti-HIV protein from an actinomycete, and its expression in Escherichia coli. Biochem Biophys Res Commun 2001, 281:1261-1265.
68. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009, 30:356-362.
69. Karim Q.A., Karim S.S.A., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
70. Karim S.S.A., Richardson B.A., Ramjee G., Hoffman I.F., Chirenje Z.M., Taha T., et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011, 25:957-966.
71. Kelley B.S., Chang L.C., Bewley C.A. Engineering an obligate domain-swapped dimer of cyanovirin-N with enhanced anti-HIV activity. J Am Chem Soc 2002, 124:3210-3211.
72. Knäblein J. Plant-based expression of biopharmaceuticals. Encyclopedia of molecular cell biology and molecular medicine 2005, 10:385-410. Wiley and Sons. 2nd ed.
73. Ko K., Tekoah Y., Rudd P.M., Harvey D.J., Dwek R.A., Spitsin S., et al. Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A 2003, 100:8013-8018.
74. Koprivova A., Altman F., Gorr G., Kopriva S., Reski R., Decker E.L. N-Glycosylation in the moss Physcomitrella patens is organized similarly to that in higher plants. Plant Biol 2003, 5:582-591.
75. Koshte V.L., Van Dijk W., Van Der Stelt M.E., Aalberse R.C. Isolation and characterization of BanLec-I, a mannoside-binding lectin from Musa paradisiac (banana). Biochem J 1990, 272:721-726.
76. Kukuruzinska M., Lennon K. Protein N-Glycosylation: molecular genetics and functional significance. Crit Rev Oral Biol Med 1998, 9:415-448.
77. Lannoo N., Van Damme E.J. Nucleocytoplasmic plant lectins. Biochim Biophys Acta 2010, 1800:190-201.
78. Lau O.S., Sun S.S. Plant seeds as bioreactors for recombinant protein production. Biotechnol Adv 2009, 27:1015-1022.
79. Lenz O., Dittmar M.T., Wagner A., Ferko B., Varauer-Uhl K., Stiegler G., et al. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J Biol Chem 2005, 280:4095-4101.
80. Li F., Vijayasankaran N., Shen A.Y., Kiss R., Amanullah A. Cell culture processes for monoclonal antibody production. MAbs 2010, 2:466-477.
81. Li Y., O'Dell S., Walker L.M., Wu X., Guenaga J., Feng Y., et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 2011, 85:8954-8967.
82. Liu X., Lagenaur L.A., Simpson D.A., Essenmacher K.P., Frazier-Parker C.L., Liu Y., et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 2006, 50:3250-3259.
83. Liu B., Zhang B., Min M., Bian H., Chen L., Liu Q., et al. Induction of apoptosis by Polygonatum odoratum lectin and its molecular mechanisms in murine fibrosarcoma L929 cells. Biochim Biophys Acta 2009, 1790:840-844.
84. Liu B., Bian H., Bao J. Plant lectins: potential antineoplastic drugs from bench to clinic. Cancer Lett (Shannon, Irel) 2010, 287:1-12.
85. Loos A., Van Droogenbroeck B., Hillmer S., Grass J., Kunert R., Cao J., et al. Production of monoclonal antibodies with a controlled N-glycosylation pattern in seeds of Arabidopsis thaliana. Plant Biotechnol J 2010, 9:179-192.
86. Luo X.M., Lei M.Y., Feidi R.A., West A.P., Balazs A.B., Bjorkman P.J., et al. Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog 2010, 6:1661-1671.
87. Ma J.K., Drake P.M.W., Christou P. The production of recombinant pharmaceutical proteins in plants. Nature 2003, 4:794-805.
88. Maclean J., Koekemoer M., Olivier A.J., Stewart D., Hitzeroth I.I., Rademacher T., et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J GenVirol 2007, 88:1460-1469.
89. Marillonnet S., Giritch A., Gils M., Kandzia R., Klimyuk V., Gleba Y. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci U S A 2004, 101:6852-6857.
90. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
91. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
92. Matoba N., Husk A.S., Barnett B.W., Pickel M.M., Arntzen C.J., Montefiori D.C., et al. HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-Cell mitogenic activity. PLoS One 2010, 5:e11143.
93. Mayer K.H., Peipert J., Fleming T., Fullem A., Moench T., Cu-Uvin S., et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis HIV/AIDS 2001, 32:476-482.
94. McFadden K., Cocklin S., Gopi H., Baxter S., Ajith S., Mahmood N., et al. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins: Struct Funct Bioinf 2007, 67:617-629.
95. McGaughey G.B., Citron M., Danzeisen R.C., Freidinger R.M., Garsky V.M., Hurni W.M., et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003, 42:3214-3223.
96. McGowan I. Microbicide development. Public health aspects of HIV/AIDS in low and middle income countries 2009, 115-133. Springer Science and Business Media, Part I. D.D. Celentano, C. Beyrer (Eds.).
97. Mett V., Farrance C.E., Green B.J., Yusibov V. Plants as biofactories. Biologicals 2008, 36:354-358.
98. Minces L.R., McGowan I. Advances in the development of microbicides for the prevention of HIV infection. Curr Infect Dis Rep 2010, 12:56-62.
99. Mori T., Boyd M.R. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother 2001, 45:664-672.
100. Mori T., Shoemaker R.H., McMahon J.B., Gulakowski R.J., Gustafson K.R., Boyd M.R. Construction and enhanced cytotoxicity of a cyanovirin-N-Pseudomonas exotoxin conjugate against human immunodeficiency virus-infected cells. Biochem Biophys Res Commun 1997, 239:884-888.
101. Mori T., O'Keefe B.R., Raymond C., Sowder R.C., Bringans S., Gardella R., et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005, 280:9345-9353.
102. Morris G.C., Lacey C.J.N. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 2010, 23:57-63.
103. Morris G., Chindrove S., Woodhall S., Wiggins R., Vcelar B., Lacey C. A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing antibodies (2FS, 2G12, 4E10) (MabGel). Microbicides 2010, 229. (Pittsburgh, PA), LB1.
104. Moscicki A. Vaginal microbicides: where are we and where are we going?. J Infect Chemother 2008, 14:337-341.
105. Moulaei T., Shenoy S.R., Giomarelli B., Thomas C., McMahon J.B., Dauter Z., et al. Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity. Structure 2010, 18:1104-1115.
106. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647.
107. Nabatov A.A., de Jong M.A., de Witte L., Bulgheresi S., Geijtenbeek T.B. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells. Virology 2008, 378:323-328.
108. O'Keefe B.R. Biologically active proteins from natural product extracts. J Nat Prod 2001, 64:1373-1381.
109. O'Keefe B.R., Vojdani F., Buffa V., Shattock R.J., Montefiori D.C., Bakke J., et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A 2009, 106:6099-6104.
110. O'Keefe B.R., Giomarelli B., Barnard D.L., Shenoy S.R., Chan P.K.S., McMahon J.B., et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol 2010, 84:2511-2521.
111. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75:8340-8347.
112. Patel J., Zhu H., Menassa R., Gyenis L., Richman A., Brandle J. Elastin-like polypeptide fusions enhance the accumulation of recombinant proteins in tobacco leaves. Trans Res 2007, 16:239-249.
113. Paul M., Ma J.K.-C. Plant-made pharmaceuticals: leading products and production platforms. Biotechnol Appl Biochem 2011, 58:58-67.
114. Percudani R., Montanini B., Ottonello S. The anti-HIV cyanovirin-N domain is evolutionarily conserved and occurs as a protein module in eukaryotes. Proteins: Struct Funct Bioinf 2005, 60:670-678.
115. Peumans W.J., Van Damme E.J. Lectins as plant defense proteins. Plant Physiol 1995, 109:347-352.
116. Pironne V., Wigdahl B., Krebs F.C. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res 2011, 90:168-182.
117. Pogue G.P., Lindbo J.A., Garger S.J., Fitzmaurice W.P. Making an ally from an enemy: plant virology and the new agriculture. Annu Rev Phytopathol 2002, 40:45-74.
118. Pozzi G., Giomarelli B., Maggi T., Medaglini D., Mori T., Boyd M. Mucosal delivery of microbicides by recombinant commensal bacteria: expression of the HIV-inactivating protein cyanovirin-N in gram-positive bacteria. AIDS 2001, 15:S58.
119. Rademacher T., Sack M., Arcalis E., Stadlmann J., Balzer S., Altmann F., et al. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J 2008, 6:189-201.
120. Ramessar K., Rademacher T., Sack M., Stadlmann J., Platis D., Stiegler G., et al. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc Natl Acad Sci U S A 2008, 105:3727-3732.
121. Regnard G.L., Halley-Stott R.P., Tanzer F.L., Hitzeroth I.I., Rybicki E.P. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J 2010, 8:38-46.
122. Reina J.J., Bernardi A., Clerici M., Rojo J. HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Med Chem 2010, 2:1141-1159.
123. Rodriguez M., Ramirez N.I., Ayala M., Freyre F., Perez L., Triguero A., et al. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol Bioeng 2004, 89:188-194.
124. Rovenská G.Z., Zemek R. Host plant preference of aphids, thrips and spider mites on GNA-expressing and control potatoes. Phytoparasitica 2006, 34:139-148.
125. Rybicki E.P., Martin D.P. Virus-derived ssDNA vectors for the expression of foreign proteins in plants. Curr Top Microbiol Immunol 2011, [Oct 29 [Epub ahead of print]].
126. Sack M., Paetz A., Kunert R., Bomble M., Hesse F., Stiegler G., et al. Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J 2007, 21:1655-1664.
127. Sainsbury F., Lomonossoff G.P. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol 2008, 148:1212-1218.
128. Sainsbury F., Lavoie P., D'Aoust M., Vézina L., Lomonossoff G.P. Expression of multiple proteins using full-length and deleted versions of cowpea mosaic virus RNA-2. Plant Biotechnol J 2008, 6:82-92.
129. Sainsbury F., Sack M., Stadlmann J., Quendler H., Fischer R., Lomonossoff G.P. Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLoS One 2010, 5:1-9.
130. Scanlan C.N., Pantophlet R., Wormald M.R., Saphire E.O., Stanfield R., Wilson I.A., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of 132 mannose residues on the outer face of gp120. J Virol 2002, 76:7306-7321.
131. Schähs M., Strasser R., Stadlmann J., Kunert R., Rademacher T., Steinkellner H. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J 2007, 5:657-663.
132. Scherer E.M., Leaman D.P., Zwick M.B., McMichael A.J., Burton D.R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 2010, 107:1529-1534.
133. Schols D. HIV coreceptor CXCR4 antagonists. Curr Opin HIV AIDS 2006, 1:361-366.
134. Schols D. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res 2011, 71:216-226.
135. Sexton A., Drake P.M., Mahmood N., Harman S.J., Shattock R.J., Ma J.K. Transgenic plant production of cyanovirin-N, an HIV microbicide. FASEB J 2006, 20:356-358.
136. Sexton A., Harman S., Shattock R.J., Ma J.K. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 2009, 23:3590-3600.
137. Shaaltiel Y., Bartfeld D., Hashmueli S., Baum G., Brill-Almon E., Galili G., et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 2007, 5:579-590.
138. Shenoy S.R., O'Keefe B.R., Bolmstedt A.J., Cartner L.K., Boyd M.R. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther 2001, 297:704-710.
139. Simek M.D., Wasima R., Priddy F.H., Pung P., Carrow E., Laufer D.S., et al. Human immunodeficiency virus Type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83:7337-7348.
140. Smee D.F., Bailey K.W., Wong M.H., O'Keefe B.R., Gustafson K.R., Mishin V.P., et al. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 2008, 80:266-271.
141. Sreevidya V.S., Hernandez-Oane R.J., So R.B., Sullia S.B., Stacey G., Ladha J.K., et al. Expression of the legume symbiotic lectin genes psl and gs52 promotes rhizobial colonization of roots in rice. Plant Sci 2005, 169:726-736.
142. Strasser R., Altmann F., Mach L., Glössl J., Steinkellner H. Generation of Arabidopsis thaliana plants with complex N-glycans lacking β1, 2-linked xylose and core α1, 3-linked fucose. FEBS Lett 2004, 561:132-136.
143. Strasser R., Castilho A., Stadlmann J., Kunert R., Quendler H., Gattinger P., et al. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous 1, 4-galactosylated N-glycan profile. J Biol Chem 2009, 284:20479-20485.
144. Tanaka H., Chiba H., Inokoshi J., Kuno A., Sugai T., Takahashi A., et al. Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 2009, 106:15633-15638.
145. Triguero A., Cabrera G., Cremata J.A., Yuen C., Wheeler J., Ramírez N.I. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J 2005, 3:449-457.
146. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
147. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622.
148. Tsai C.C., Emau P., Jiang Y., Tian B., Morton W.R., Gustafson K.R., et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89. 6P in macaques. AIDS Res Hum Retroviruses 2003, 19:535-541.
149. Twyman R.M., Stöger E., Schillberg S., Christou P., Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol 2003, 21:570-578.
150. Twyman R.M., Schillberg S., Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 2005, 10:185-218.
151. Twyman R.M., Schillberg S., Fischer R. The production of vaccines and therapeutic antibodies in plants. Molecular farming in plants: recent advances and future prospects 2012, 145-159. Springer, NY. A. Wang, S. Ma (Eds.).
152. UNAIDS Report on the global HIV-1/AIDS epidemic. In: UNAIDS 2010.
153. UNAIDS Report on the global HIV-1/AIDS epidemic. In: UNAIDS 2011.
154. Van Damme E.J.M., Allen A.K., Peumans W.J. Isolation and characterization of a lectin with exclusive specificity towards mannose from snowdrop (Galanthus nivalis) bulbs. FEBS Lett 1987, 215:140-144.
155. Van Damme E., Peumans W., Barre A., Rouge P. Plant lectins: a composite of several distinct families of structurally and evolutionary related proteins with diverse biological roles. Crit Rev Plant Sci 1998, 17:575-692.
156. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977.
157. Van Damme E.J., Barre A., Rougé P., Peumans W.J. Cytoplasmic/nuclear plant lectins: a new story. Trends Plant Sci 2004, 9:484-489.
158. Van Der Veen M.J., van Ree R., Aalberse R.C., Akkerdaas J., Koppelman S.J., Jansen H.M., et al. Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins. J Allergy Clin Immunol 1997, 100:327-334.
159. Van Montfort T., Nabatov A.A., Geijtenbeek T.B.H., Pollakis G., Paxton W.A. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol 2011, 178:3177-3185.
160. Veazy R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003, 9:343-346.
161. Veluthambi K., Gupta A.K., Sharma A. The current status of plant transformation technologies. Curr Sci 2003, 84:368-380.
162. Vianna G.R., Aragão F.J.L., Rech E.L. A minimal DNA cassette as a vector for genetic transformation of soybean (Glycine max). Genet Mol Res 2011, 10:382-390.
163. Walker L.M., Phogat S.K., Chan-Hui P., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-288.
164. Wang Z., Zhang K., Sun X., Tang K., Zhang J. Enhancement of resistance to aphids by introducing the snowdrop lectin gene gna into maize plants. J Biosci 2005, 30:627-638.
165. West A.P., Galimidi R.P., Foglesong C.P., Gnanapragasam P.N.P., Huey-Tubman K.E., Klein J.S., et al. Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol 2009, 83:98-104.
166. Wu X., Yang Z., Li Y., Hogerkorp C., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
167. Xiong S., Fan J., Kitazato K. The antiviral protein cyanovirin-N: the current state of its production and applications. Appl Microbiol Biotechnol 2010, 86:805-812.
168. Xu H., Song L., Kim M., Holmes M.A., Kraft Z., Sellhorn G., et al. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol 2010, 84:1076-1088.
169. Yang J., Barr L.A., Fahnestock S.R., Liu Z.-B. High yield recombinant silk-like protein production in transgenic plants through protein targeting. Transgenic Res 2005, 14:313-324.
170. Yu X., Pollock D., Duval M., Lewis C., Meade H., Cavacini L., et al. Neutralization of HIV by milk expressed antibody. Poster presented at Federation of Clinical Immunology Societies, Boston 2010.
171. Zappe H., Snell M.E., Bossard M.J. PEGylation of cyanovirin-N, an entry inhibitor of HIV. Adv Drug Deliv Rev 2008, 60:79-87.
172. Zhao S., Zhao Y., Li S., Zhao J., Zhang G., Wang H., et al. A novel lectin with highly potent antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the edible wild mushroom Russula delica. Glycoconj J 2010, 27:259-265.
173. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
174. Ziółkowska N.E., Wlodawer A. Structural studies of algal lectins with anti-HIV activity. Acta Biochim Pol 2006, 53:617-626.
175. Ziółkowska N.E., O'Keefe B.R., Mori T., Zhu C., Giomarelli B., Vojdani F., et al. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 2006, 14:1127-1135.
176. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.